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Abstract: (1) Background: Treatment of patients with rheumatoid arthritis (RA) with an anti-IL-6
receptor (anti-IL-6R) monoclonal antibody (tocilizumab) has been found to influence iron metabolism.
The objective of the present study was to ascertain whether changes in iron metabolism induced
by anti-IL-6R biologic therapy were independently associated with an increased infection risk.
(2) Methods: A prospective longitudinal study of patients with RA treated with tocilizumab was
conducted. RA patients treated with an antitumor necrosis factor α monoclonal antibody were also
included as a control group. The primary outcome was occurrence of infection during the first
24 months of biologic therapy. (3) Results: A total of 15 patients were included, with a mean age
of 51.0 ± 4,1 and 73.3% (n = 11) female. A multivariate survival regression model, adjusted for
confounding factors, was fitted for each of the iron metabolism variables. Hazard ratios for being
above the median of each parameter was considered. Transferrin saturation above the median value
(>32.1%) was associated with a higher infection risk (HR 4.3; 95%CI 1.0–19.69; p = 0.05). Similarly,
although non-significantly, higher serum iron was strongly associated with infection occurrence.
(4) Conclusions: This study identified a probable association between infection risk and higher serum
iron and transferrin saturation in patients with RA on anti-IL-6R biologic therapy. We suggest that
both these parameters should be considered relevant contributing factors for infection occurrence in
patients on anti-IL-6R therapy.
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1. Introduction
Infection is a frequent complication during the natural clinical evolution of rheumatoid arthritis
(RA), contributing to disease-associated morbidity and mortality [1]. Age-adjusted mortality in RA
might be increased about twofold when compared to the general population, and infectious diseases
are one of the leading causes of death [2]. This infection risk has been found to be influenced by
several disease-related conditions, patient-associated comorbidities, and the immunomodulatory drugs
used. Scores of disease activity, such as the disease activity score 28 (DAS-28), have been found to
correlate with infection risk [1,3]. Corticosteroids, synthetic disease-modifying anti-rheumatic drugs
(DMARDs), and biologic DMARDs may also suppress the immune response, which might translate
into an additional risk for infection [2,4].
In the complex pathophysiology of RA, interleukin-6 (IL-6) overproduction is of major relevance. IL-6
is a pleiotropic cytokine with a role in eliciting the acute-phase response in the liver, B-cell proliferation
and antibody production, and T-cell differentiation and cytotoxicity [5]. Chronic inflammatory states,
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such as the one present in RA, through increased levels of IL-6 and other cytokines, result in an increased
transcription of the HAMP gene in the liver, which encodes hepcidin [6]. After binding to its receptor
in hepatocytes, IL-6 induces a Janus kinase 1 (JAK1)-mediated phosphorylation of STAT3, which in
turn activates the transcription of the HAMP gene [6]. Hepcidin is an iron regulatory hormone [7]
whose best-documented activity is binding to and promoting endocytosis and degradation of ferroportin,
the only known iron exporter expressed in cells involved in iron metabolism [7–9]. High concentrations
of circulating hepcidin, characteristic of inflammatory states, results in low expression of ferroportin in
duodenal enterocytes, hepatocytes, Kupffer cells, and splenic macrophages, decreasing iron export to the
extracellular fluid and plasma [7,8]. The result, called hypoferremia of inflammation, has been proposed
to be evolutionarily advantageous [9]. Three adaptive functions have been proposed for the hypoferremia
of inflammation: inhibition of extracellular bacterial growth by sequestering available iron (considering
that most infectious agents need to scavenge iron from the host to multiply); protection from the toxicity
caused by high levels of iron and heme released during tissue necrosis and erythrocyte destruction;
and increased transferrin capacity to bind to iron released during infection and inflammation [6,8].
Considering the IL-6 overproduction observed in RA, one of the biologic DMARDs used
successfully for its treatment is tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal
antibody designed to block IL-6 signaling [10]. In patients with RA treated with tocilizumab, infection
is considered the most frequent adverse event and respiratory infections are the most frequently
documented [11–13]. Although clinical trials initially reported low infection rates associated with
tocilizumab therapy in patients with RA [11–13], some observational studies of real-life registries have
found higher infection rates [5]. Comparisons of infection rates between anti-IL-6R and antitumor
necrosis factor α (TNFα) therapy have also been conducted, with some observational cohort studies
finding a higher infection rate in tocilizumab [14,15].
The IL-6 signal blockade may suppress hypoferremia of inflammation [5]. It has been demonstrated
that blocking IL-6 or TNFα pathways with tocilizumab or anti-TNFα monoclonal antibodies resulted
in significantly lower serum hepcidin and significantly higher serum iron [16]. However, the effect
on hepcidin was noted to be stronger in patients treated with tocilizumab when compared with
patients treated with anti-TNFα monoclonal antibodies [16]. Analysis of the relationship between
these parameters and infection risk observed in this type of patients has never been evaluated before.
The objective of the present study was to ascertain whether changes in iron metabolism induced
by anti-IL-6R biologic therapy were associated with an increased risk of infection.
2. Results
This was a prospective longitudinal study of patients with a diagnosis of RA and treated with
an anti-IL-6R biologic. RA patients treated with an anti-TNFα were also included as a control group.
Both groups had a 24-month follow-up, with serum samples collected every semester and any infections
during this period registered by clinical interview.
A total of 15 patients were included, with a mean age of 51.0± 4.1 and 73.3% (n = 11) female. All patients
completed the follow-up time without censoring. Mean disease duration was 10.8 ± 9.5 years. Regarding
biologic DMARD therapy, 10 patients were treated with an anti-IL-6R monoclonal antibody (tocilizumab)
and 5 with an anti-TNFα monoclonal antibody (either infliximab, golimumab, or adalimumab). Baseline
characteristics and additional drugs used at any time during follow-up are summarized in Tables 1 and 2,
respectively. Corticosteroid daily dosages were relatively low (median = 5 mg/day, IQR 5–10 mg/day,
maximum of 20 mg/day, in prednisolone-equivalent dosages).
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Table 1. Baseline characteristics.








51.0 ± 4.1 51.1 ± 5.7 51.0 ± 5.4 0.9986
11 (73.3%) 7 (70%) 4 (80%) 0.6900
Disease-related characteristics
Disease duration (years) 10.8 ± 9.5 10,7 ± 9.7 10.9 ± 10.8 0.7815
First biologic therapy 8 (53.3%) 4 (40%) 4 (80%) 0.1573
Comorbidities
Hypertension 7 (46.7%) 5 (50%) 2 (40%) 0.7237
Diabetes mellitus 3 (20%) 2 (20%) 1 (20%) 1.0000
Structural lung disease 3 (20%) 2 (20%) 1 (20%) 1.0000
Urolithiasis 2 (13.3%) 2 (20%) 0 0.2994
Tympanic perforation 2 (13.3%) 2 (20%) 0 0.2994
Gastrectomy 1 (6.7%) 1 (10%) 0 0.2994
Anti-IL-6R—anti-interleukin-6 receptor; anti-TNFα—antitumor necrosis factor α.
Table 2. Additional drugs used. 1




(n = 5) p-value
Proton pump inhibitor 9 (60%) 6 (60%) 1 (60%) 1.0000
Corticosteroid 11 (73.3%) 8 (80%) 2 (60%) 0.4250
Methotrexate 11 (73.3%) 6 (60%) 5 (100%) 0.1106
Sulfasalazine 4 (26.7%) 1 (10%) 3 (60%) 0.0461
1 At any time during follow-up. Anti-IL-6R—anti-interleukin-6 receptor; anti-TNFα—antitumor necrosis factor α.
2.1. Iron Metabolism
Median serum iron levels were significantly higher in the anti-IL-6R group (131.3 ug/dL (IQR
112.0–135.3 ug/dL) vs. 91.0 ug/dL (IQR 77.8–109.0 ug/dL); p = 0.028). Median serum IL-6 levels
were also higher in the anti-IL-6R group (58.6 pg/mL (IQR 23.5–134.4 pg/mL) vs. 21.2 pg/mL (IQR
6.4–41.0 pg/mL); p = 0.090)—Figure 1a,b—which is consistent with the known mechanism of action
of tocilizumab and corroborates good patient adherence. The relationship between serum IL-6 and
hepcidin levels tended to be inverse (Figure 1c) and there was a direct positive relationship between
hepcidin and serum iron levels (p = 0.018)—Figure 1d.
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Figure 1. Iron metabolism. (a) Box plots showing median levels of serum iron in the two groups;
(b) box plots showing median levels of serum IL-6 in the two groups; (c) inverse relationship between
hepcidin and IL-6 levels; (d) positive correlation between serum iron and hepcidin, with the linear
regression line shown. Please see text for details.
2.2. Infection Risk
During follow-up, a total of 29 infections were registered, 89.66% (n = 26) in the anti-IL-6R
group and 10.34% (n = 3) in the anti-TNFα group. The types of infections are summarized in Table 3.
Definitive microbiological identification of the infectious agents was not extensively pursued. The type
of infectious agent (bacterial, viral, or fungal) was mainly presumptive considering clinical, analytical,
and epidemiological data. Three infections were considered serious, 1 in the anti-IL-6R group and 2 in
the anti-TNFα group. All serious infections were pneumonias requiring inpatient intravenous therapy.
None of the infections resulted in death.
Table 3. Type of infection in subgroups.
Anti-IL-6R 1 Anti-TNFα 2
Respiratory 9 Respiratory 3
Genitourinary 8 - -
Skin and soft tissue 4 - -
Ear 3 - -
Gastrointestinal 1 - -
Eye 1 - -
1 26 infections in 8 patients. 2 3 infections in 1 patient. Anti-IL-6R—anti-interleukin-6 receptor; anti-TNFα—antitumor
necrosis factor α.
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A first non-adjusted analysis of mean serum iron levels and number of infections during follow-up
revealed an association between higher serum iron and a higher number of infections (Poisson
regression, p = 0.030)—Figure 2.
Figure 2. Relationship between mean serum iron level and number of infections during follow-up of
patients both on anti-IL-6R (green squares) and anti-TNFα (blue circles) subgroups. The Poisson regression
curve is depicted (dashed red), p = 0.030. Anti-IL-6R—anti-interleukin-6 receptor; anti-TNFα—antitumor
necrosis factor α.
Next, a multiple failure-time survival analysis was performed through fitting of an Anderson-Gill
Cox proportional hazards regression model. Univariate analysis of patient’s characteristics identified
a higher risk of infection in the presence of diabetes mellitus and a lower risk of infection in the presence
of corticosteroid therapy—Table 4.
Table 4. Univariate survival analysis results.
Patient and Disease-Associated Variables Hazard Ratio p-value 95% Confidence Interval
Constant baseline variables
Age 1.004915 0.800 0.9675943–1.043676
Male gender 0.2343794 0.124 0.0369132–1.488188
Disease duration 0.9324102 0.300 0.8169411–1.0642
Anti-IL-6R therapy 2.66909 0.335 0.3622716–19.66492
First-line therapy 0.9597915 0.955 0.2281255–4.038127
Hypertension 2.357254 0.295 0.4742625–11.71639
Diabetes mellitus 4.870464 0.023 1.249398–18.98629
Structural lung disease 1.031864 0.964 0.2653836–4.012092
Urolithiasis 2.224302 0.417 0.3229469–15.31991
Proton pomp inhibitor therapy 0.9087983 0.896 0.2176265–3.7951
Time-varying variables
DAS28 0.7218875 0.357 0.3610093–1.443513
Erythrocyte sedimentation rate (mm/1hr) 0.9997664 0.994 0.9405976–1.062657
Corticosteroids 0.2458265 0.073 0.0529271–1.141771
Prednisolone daily dose (mg) 1.100572 0.394 0.8829673–1.371804
Methotrexate 0.3458809 0.185 0.0719138–1.66357
Methotrexate weekly dose (mg) 0.9233559 0.159 0.8264177–1.031665
Sulfasalazine 1 0.3954318 0.353 0.0558712–2.798691
1 Sulfasalazine daily dose relative risk estimates were not calculated due to the low number of patients on this drug
(n = 4) and non-significant daily dose variation. DAS28—disease activity score 28.
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Considering the potential confounding variables identified in the univariate analysis, a multivariate
survival regression model, adjusted for the presence of diabetes mellitus and for corticosteroid therapy,
was fitted for each of the iron metabolism variables (Table 5, Figure 3). Hazard ratios for being
above the median of each parameter distribution was considered. Transferrin saturation above
the median value (>32.1%) was associated with a higher infection risk (HR 4.3; 95%CI 1.0–19.69;
p = 0.05). This result was similar when a sub-analysis was performed in the anti-IL-6R group (HR 6.46;
95%CI 1.05–39.72; p = 0.044). Ferritin above the median value (>72 mg/dL) presented as a protective
factor (HR 0.16; 95%CI 0.05–0.53; p = 0.003). As serum iron above the median value was, although
non-significantly, still strongly associated with a higher infection risk (HR = 3.2 for all patients),
we performed a quartile sub-analysis that showed a consistently higher risk of infection for each higher
quartile (Table 6, Figure 4).
Table 5. Multivariate survival analysis for iron metabolism parameters. Hazard ratios presented are
for being above the median for each variable (relative to being below the median).
Iron Metabolism Parameters Hazard Ratio p-value 95% Confidence Interval
Serum iron
All 3.163589 0.089 0.8386898–11.93325
Anti-IL-6R 2.570872 0.238 0.5356937–12.33799
Transferrin
All 1.314897 0.637 0.4223613–4.09354
Anti-IL-6R 1.874245 0.447 0.3708102–9.4733
TIBC
All 1.314897 0.637 0.4223613–4.09354
Anti-IL-6R 1.874245 0.447 0.3708102–9.4733
Transferrin Saturation
All 4.321854 0.050 0.999262–18.69222
Anti-IL-6R 6.461889 0.044 1.051171–39.72334
Ferritin
All 0.600787 0.003 0.048141–0.5322946
Anti-IL-6R 0.2356835 0.112 0.0395527–1.404372
Hepcidin All 2.183736 0.465 0.2691971–1.71454
Anti-IL-6R 9.408961 0.084 0.7420833–119.2973
IL-6
All 2.654745 0.271 0.4658854–15.12748
Anti-IL-6R 2.173225 0.335 0.4478064–10.54677
TIBC—Total iron binding capacity; anti-IL-6R—anti-interleukin-6 receptor.
Figure 3. Kaplan–Meier survival curves for transferrin saturation (a) and ferritin (b) values above
(solid lines) or below (dashed lines) the median.
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Table 6. Multivariate survival analysis for quartile distribution of serum iron.
Hazard Ratio p-value 95% Confidence Interval
All
Q1 (1) - -
Q2 2.654559 0.363 0.3244244–21.72057
Q3 3.633011 0.221 0.4601984–28.6806
Q4 12.50757 0.085 0.7074825–221.1213
Anti-IL-6R
Q1 (1) - -
Q2 0.1373109 0.239 0.0050287–3.749356
Q3 0.6592579 0.596 0.1414934–3.071671
Q4 1,112208 0,909 0,1806099–6,849054
Q—Quartile; anti-IL-6R—anti-interleukin-6 receptor.
Figure 4. Kaplan–Meier survival curves for each quartile of serum iron values.
3. Discussion
This was a prospective longitudinal pilot study designed to evaluate whether changes in iron
metabolism induced by anti-IL-6R biologic therapy were independently associated with an increased
risk of infection in patients with RA. Higher infection risk was associated with higher serum iron and
transferrin saturation.
Baseline characteristics were as expected for a cohort of patients with RA. Gender, median age,
disease duration, and co-morbidities of patients on anti-IL-6R therapy did not differ when compared
with a subgroup of patients on anti-TNFα. Non-biologic DMARD therapy use was also similar, with
the exception of a significantly higher sulfasalazine use in the anti-TNFα group. Posterior analysis
did not find a higher relative risk of infection in sulfasalazine users, and this difference was not
considered relevant.
As expected, patients on anti-IL-6R monoclonal antibody therapy tended to have higher levels of
free serum IL-6 than patients on anti-TNFα. These data are in accordance with drug pharmacodynamics
and result from a diminished serum clearance of receptor-bound IL-6. The relationship between
serum IL-6 and hepcidin levels seemed to be inverse, most probably as a result of a reduced IL-6
receptor-JAK1-STAT3 signal for HAMP gene transcription due to the IL-6-receptor blockade. Therefore,
higher IL-6 serum levels (and consequently, a higher IL-6 receptor blockade) were associated with a lower
hepcidin concentration. This was expected to have resulted in less endocytosis and degradation of
ferroportin in duodenal enterocytes, hepatocytes, Kupffer cells, and splenic macrophages, higher iron
efflux and, consequently, higher serum iron levels in patients on anti-IL-6R therapy. However,
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an unexpected positive linear correlation between serum iron and hepcidin was obtained, and higher
levels of hepcidin were associated with higher levels of serum iron. This relationship may have been
affected by the presence of unmeasured confounding regulatory factors of hepcidin production or may
have derived from the stimulatory effect that serum iron has on hepcidin transcription in hepatocytes,
through a mechanism of extracellular iron sensing [6].
In the univariate analysis of patient and disease-related characteristics, diabetes mellitus was
the only statistically significant risk predictor for infection. The relationship between diabetes and
infection risk is well-known in the general population and is expected to be similar in patients on
biologic DMARD therapy. Corticosteroid therapy, on the other hand, tended to constitute a protective
independent factor for infection occurrence in this study. It is commonly accepted that corticosteroid
use increases infection risk [2], but it should be noted that the median daily dose per patient in our study
was 5 mg/day. Such low dosages may have an immunomodulatory rather than an immunosuppressive
effect, such that controlling chronic inflammation may translate into a lower infection risk. In light of
this, survival analysis was adjusted for these two variables.
The relationship found between higher serum iron levels and transferrin saturation, and a higher
infection risk was initially proposed and expected. Infective microorganisms use available iron as
a catalytic component of enzymes that mediate many redox reactions, making it crucial for energy
production and proliferation [6]. Concentration of iron in plasma and extracellular fluid decreases
dramatically within hours of infection or other inflammatory stimuli through a cytokine-driven increase
in hepcidin concentration [8]. This adaptative function of hepcidin is of particular importance when
most common extracellular infective microorganisms are considered [8]. For intracellular agents
(e.g., Legionella pneumophila and Mycobacterium tuberculosis) the hepcidin–ferroportin axis may play
an opposing role, as iron release from infected cells into plasma could deprive microorganisms of
the iron they need to grow [8]. Even without a definitive microbiologic identification, the infections
reported here have a very low probability of being caused by intracellular organisms, based on clinical
and epidemiological data. Furthermore, assistant physicians considered the majority of infections as
being caused by extracellular bacteria and treated them accordingly and successfully. Infections were,
as stated in previously published work [15], mainly respiratory, and none were considered serious.
Transferrin saturation presented as a significant predictive factor for infection occurrence when above
32.1% (median). Although not statistically significant, a very consistent and progressive increase in
the hazard ratio for each quartile of serum iron levels (when compared with the first quartile) was
obtained. The reduced number of patients included may have contributed to a loss of statistical
power. Additionally, a statistically significant protective effect of ferritin on infection risk was obtained.
Higher serum ferritin probably reflects higher cellular ferritin and iron storage as a consequence of
ferroportin degradation and lower serum iron availability.
This study has some limitations. Blood sampling was not performed before biologic therapy was
initiated, which limited the evaluation of the dynamic evolution of iron-related parameters. A small
number of patients were included, and the anti-TNFα control group was smaller than the anti-IL-6R
group, which might have limited statistical power. However, to the best of our knowledge, this
investigation is the first to evaluate the relationship between iron metabolism and infection risk in
patients with RA on anti-IL-6R biologic therapy, and it has consistently demonstrated that a trend in
iron metabolism for a higher extracellular iron availability predicts infection occurrence. Given its
intrinsically potent immunosuppressor effect, we would not suggest that elevated iron availability
is the only mechanism through which tocilizumab increases infection risk, but our results show that
it should be considered as a relevant contributing factor. Studies with larger cohorts are needed to
confirm these data.
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4. Materials and Methods
4.1. Study Design and Patient Eligibility
We conducted an observational prospective longitudinal study of patients with seropositive RA
treated at the Systemic Immune-Mediated Diseases Unit in Portugal, under biologic DMARD therapy
with either anti-IL-6R or anti-TNFα. All patients gave written informed consent for participation in
the study, which was conducted in accordance with the Declaration of Helsinki, and after approval
by the Ethics Committee of Hospital Professor Doutor Fernando Fonseca. Patients entered the study
at the start of biological therapy and were followed up for 24 months. All blood samples were
collected in the morning without fasting. Patients were 18 years old or older. Exclusion criteria were
pregnancy; chronic kidney disease KDIGO classification 4 or higher; chronic liver disease Child–Pugh
B or higher; cancer; transfusion therapy, iron or erythropoietin supplementation during or three
months before starting biologic therapy; primary or secondary immunodeficiency not related with the
immunomodulatory therapy; refusal or inability to sign informed consent.
4.2. Assessments
We collected demographic, clinical, and therapy-related data such as comorbidities, disease
activity, and type and time of exposure to additional non-biologic immunomodulatory therapy. Disease
activity was measured with the DAS28 score [17] at the time of each blood sample collection.
Hepcidin and IL-6 plasma concentrations were measured using commercial ELISA kits (DY8307 and
DY206, respectively—R&D systems, Minneapolis, MN, USA). All other biochemical and hematological
parameters were measured using standard laboratory techniques. Blood samples from infection episodes
were excluded.
4.3. Outcomes
The primary outcome was occurrence of infection during the first 24 months of biologic therapy.
Infections were identified through clinical interviews during each regular follow-up visit at our clinic.
Infections were grouped into respiratory (including upper and lower respiratory tract infections);
genitourinary (including cystitis), pyelonephritis, and vulvovaginitis; skin and soft tissue (including
cellulitis), erysipelas, abscesses, and wound infections; ear infections (including otitis media and
externa); gastrointestinal infections (including acute gastroenteritis); and eye infections (such as purulent
conjunctivitis). Serious infections were defined as requiring hospitalization or intravenous antibiotics.
4.4. Statistical Analysis
Differences in dichotomous variables between treatment groups were assessed by Spearman’s or
Chi-square tests as appropriate. Continuous variables were compared using t-tests or Mann–Whitney
tests as appropriate, judging normality by a Shapiro–Wilk test. As an initial analysis, the number
of infection events was counted and directly compared between patients, as all patients had the
same follow-up time (24 months), and the association with mean serum iron values was tested using
a Poisson’s regression. Next, a survival analysis considering multiple failure-time data, with all patients
starting follow-up at the start of biologic drug administration (time 0). No censoring events resulted in
all patients being followed until the end of the 24 months. An Anderson–Gill Cox regression model
was used to assess each independent covariate to the outcome of interest (infection rate) to check for
potential confounders. Variables with a p-value of <0,1 were selected for inclusion in the multivariate
model for each of the components of iron kinetics available. The association of each variable of interest
(serum iron, transferrin, transferrin saturation, total iron binding capacity, ferritin, hepcidin, and IL-6)
was performed by stratifying it to above/below the median. Kaplan–Meier survival curves were
developed for significant associations. Sub-analyses with a quartile stratification was also possible.
Analyses were conducted with the use of STATA software, version 14.0 (StataCorp).
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